Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.

The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.


These press releases may also interest you

at 14:30
Disaster Management Group, a South Florida-based disaster recovery firm, announced today DMGtest, a screening tool for COVID-19 that gives results in 15 minutes. The test is the first of its kind used in Florida to screen for coronavirus. DMGtest...

at 14:02
On behalf of the Québec government, Minister of Tourism Caroline Proulx today announced the closing until further notice of tourist accommodation establishments. There are two exceptions to the rule: certain campgrounds that host snowbirds who do not...

at 14:00
Confluent Health is proud to announce their newest partnership, El Paso Physical Therapy Services (EPPTS), a physical therapist-owned rehabilitation company since 1985 specializing in the treatment of orthopedic, sports, and work-related injuries...

at 11:23
Today, Samaritan's Purse deployed its Emergency Field Hospital to New York City, New York, where the local medical infrastructure is severely overwhelmed. In cooperation with the Federal Emergency Management Agency (FEMA), New York state officials,...

at 11:01
Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. The data was...

at 11:00
As the impact of the Coronavirus (COVID-19) is now felt worldwide, we want to assure our customers and partners that we are still here to support you. Zenner's operations remain open with regular operating hours. Zenner's number one priority is...



News published on 18 november 2019 at 16:10 and distributed by: